Chase Coleman’s Ginkgo Bioworks DNA Stock Holding History

Chase Coleman’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-60,625	Closed	-$20.2M	–	108
2021 Q4	$20.2M	Hold	60,625	–	–	0.04%	105
2021 Q3	$28.1M	Buy	+60,625	New	+$29.5M	0.05%	91

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

SIG

Senator Investment Group New York $2.74B AUM 55.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Chase Coleman's DNA Position: Q1 2022 in Review

Chase Coleman sold out of Ginkgo Bioworks (DNA) in Q1 2022, closing a stake of 60,625 shares — an estimated $20.2M sold.

Chase Coleman first reported a position in DNA in Q3 2021 and held it in 2 quarters. The position peaked at $28.1M in Q3 2021. 190 funds tracked by Wall St. Rank hold DNA as of Q1 2022.

Chase Coleman reported no remaining Ginkgo Bioworks position as of Q1 2022 after selling out during the quarter.
Chase Coleman sold 60,625 Ginkgo Bioworks shares in Q1 2022, an estimated $20.2M.
Chase Coleman first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 2 quarters.
Chase Coleman's Ginkgo Bioworks position peaked at $28.1M in Q3 2021.
190 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2022.

Based on Tiger Global Management's 13F filing for Q1 2022, filed 16 May 2022.